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Non-melanoma skin cancer (NMSC) is the most frequent 
malignancy in organ transplant recipients. The aetiology 
of NMSC after transplant is multifactorial. The aim of 
this study was to determine the clinical and environmen-
tal factors involved in the development of NMSC in a 
Spanish kidney transplant population from the Mediter-
ranean region. A total of 289 patients who had received 
a kidney transplant during the period January 1996 to 
December 2010 were included in the study. Both pro-
spective and retrospective data were used. All patients 
underwent a structured interview and a complete exami-
nation of the skin. After a median follow-up of 72 months 
(range 12–180 months), 73 of the 289 patients (25.2%) 
developed 162 tumours. The ratio of basal cell carcinoma 
to squamous cell carcinoma was 2.21:1. The cumulative 
incidence of NMSC increased with the duration of im-
munosuppression, from 20.78% at 5 years, to 37.35% 
at 10 years to 53.08% at 15 years after transplantation. 
Age at the time of transplant, phototype and occupatio-
nal sun exposure were associated with a higher risk of 
NMSC. NMSC is a significant clinical problem in kid-
ney transplant recipients. This has implications for the 
development of prevention and surveillance strategies. 
Clinical and environmental factors may be used to iden-
tify those patients who are at risk for NMSC. Key words: 
transplant; renal; skin cancer; immunosuppression; risk 
factors; sun exposure.
Acta Derm Venereol 2013; 93: 422–427.
Accepted Sep 25, 2012; Epub ahead of print Jan 9, 2013
Josefa Bernat García, Department of Dermatology, Hospi-
tal Universitario Doctor Peset, ES-46020 Valencia, Spain. 
E-mail: josefabernat@hotmail.com
Non-melanoma skin cancer (NMSC) is the most common 
cancer in kidney transplant patients (1, 2). In general, 
transplant patients develop these tumours at earlier ages 
than the general population. Some patients develop 
multiple tumours that behave more aggressively with 
considerable morbidity and potential mortality (3). In ad-
dition, transplant patients are becoming more common in 
dermatology consultations due to the increased frequency 
of transplants and the increased survival of recipients. 
According to the National Transplant Organization in 
Spain, annual kidney transplants have increased from 
873 in 1988 to 2,498 in 2011 (53 kidney transplants per 
million population). Early diagnosis of premalignant 
lesions and NMSC is fundamental for reducing skin 
complications in these patients. 
We performed an observational study with the kidney 
transplant population from the Mediterranean region 
between January 1996 and December 2010. A combina-
tion of retrospective and prospective data was examined 
in order to determine the association between pheno-
typic, clinical and environmental factors with the onset 
of NMSC. The Cox proportional risk model was used to 
identify the risk factors associated with the development 
of NMSC. These factors may constitute the foundation 
for developing clinically useful predictive indices. 
MATERIALS AND METHODS
Patients 
Data were collected from 289 patients who had received a 
kidney transplant at the Doctor Peset University Hospital in 
Valencia, Spain, from January 1996 to December 2010. During 
this period 622 kidney transplants were performed in this hos-
pital. The patients were voluntarily recruited between January 
2010 and January 2012 (end date of the study), and underwent 
a structured questionnaire completed by a dermatologist and 
a complete skin examination with subsequent follow-up visits 
every 6 months until the study was finalized. The study was 
approved by the hospital’s ethics committee. All patients pro-
vided written consent. 
Demographic, clinical and environmental exposure data
Demographic information on age, race, gender, follow-up time, 
eye colour and Fitzpatrick phototype (I–IV) was collected. Pre-
transplant occupational sun exposure was used as the marker 
of ultraviolet (UV) radiation exposure (considered to be high 
when the patient had worked more than 3 years in the open air). 
Other environmental factors studied were tobacco and alcohol 
consumption and a family history of cancer. 
We also collected the duration and type of dialysis, cause of 
kidney failure and number of human leukocyte antigen (HLA) 
matches between the recipient and donor.
We grouped patients into 4 groups according to the mainte-
nance immunosuppressor treatment: group A (mTOR-sirolimus 
and/or everolimus inhibitors+mycophenolate), group B (tacroli-
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mus + mycophenolate), group C (cyclosporine + mycophenolate) 
and group D (older regimens with azathioprine).
Induction treatment was also evaluated by dividing the 
patients into 5 groups: group 0 (did not receive induction 
therapy), group 1 (induction with basiliximab: Simulect®, No-
vartis Farm, Barcelona, Spain), group 2 (induction with rabbit 
anti-thymocyte globulin: Thymoglobulin® Genzyme Europe 
Bv, Naarden, The Netherlands), group 3 (induction with equine 
anti-thymocyte globulin: ATGAM® Pfizer, Madrid, Spain) and 
group 4 (induction with monomurab-CD3: OKT3® Janssen, 
Madrid, Spain).
Skin cancer data
The number of basal cell carcinomas (BCC), squamous cell 
carcinomas (SCC), Bowen’s disease (SCC in situ) and kera-
toacanthomas were recorded. The presence of actinic keratosis 
and viral warts was also noted. Diagnosis of warts and actinic 
keratosis was based on clinical criteria, but only histologically-
confirmed cases of NMSC were included in the study. Patients 
were fully undressed for follow-up visits. Lesions that were sus-
picious of malignancy were biopsied for histological diagnosis. 
Statistical analyses 
Statistical analysis was carried out using SPSS version 19. The 
risk of skin cancer was examined using the presence of NMSC 
as the end-point. The continuous variables were expressed as 
minimum, median and maximum values. The nominal vari-
ables were expressed in absolute values and percentages. The 
cumulative incidence of skin cancer was calculated using the 
Kaplan–Meier method. 
The statistical association between the risk of developing skin 
cancer and the risk factors studied were evaluated by univariate 
analysis. In order to finally identify the individual risk of each 
of these factors, a multivariate analysis was performed using 
the Cox proportional risks model. 
RESULTS
General patient characteristics
We studied 305 patients who underwent kidney trans-
plantation at the Doctor Peset University Hospital in 
Valencia, Spain, from January 1996 to December 2010. 
We excluded 16 patients (15 patients due to have re-
ceived more than one transplant and one patient due 
to death during follow-up), with a total of 289 patients 
included in the study. The median follow-up was 72 
months (range 12–180 months).
Mean age at the time of transplant was 52.2 years 
(range 13–78 years). 
The clinical and demographic characteristics of the 
patients are shown in Table I.
Skin cancer
Of the 289 patients, 73 (25.2%) developed a total of 162 
NMSC, of which 41 were SCC, 91 BCC, 25 Bowen’s di-
sease and 5 keratoacanthomas. The BCC/SCC ratio was 
2.21:1. If we consider only the NMSC appearing in the 
first 5 years, the respective ratio was 3.5, indicating an 
earlier relative BCC appearance. Of the 73 patients who 
developed NMSC, 38 had only 1 tumour, 30 had between 
2 and 5 tumours and 5 patients developed more than 5 
tumours. Of the 289 patients, 10 had developed some 
type of NMSC prior to transplant. Five of these 10 pa-
tients continued developing NMSC after the transplant.
The mean time from transplant until diagnosis of the 
first NMSC was 58.5 months.
Table I. Clinical characteristics of 289 patients with kidney 
transplant
Skin cancer
Without (n = 216) 
n (%)
With (n = 73) 
n (%)
Age at first transplantation, years   51 (13–73) 56 (34–78)
Follow-up, years     5 (1–15) 10 (1–15)
Dialysis, years     3 (1–13)   3 (1–10)
Sex
   Female
   Male
  90 (41.7)
126 (58.3)
29 (39.7)
44 (60.3)
Phototype
   I–II
   ≥ III
106 (49.1)
110 (50.9)
55 (75.3)
18 (24.7)
Eye colour
   Light eyes
   Dark eyes
  51 (23.6)
165 (76.4)
28 (38.4)
45 (61.6)
Occupational sun exposure
   Low 
   High
209 (96.8)
    7 (3.2)
29 (39.7)
44 (60.3)
Dialysis type
   Haemodialysis
   Peritoneal
   Both
154 (71.3)
  46 (21.3)
  16 (7.4)
58 (79.5)
  6 (8.2)
  9 (12.3)
Human leukocyte antigen matches
   Not indicated
   1–2
   3–4
   ≥5
  17 (7.9)
  40 (18.5)
  99 (45.8)
  60 (27.8)
  6 (8.2)
16 (21.9)
29 (39.7)
22 (30.1)
Immunosuppression treatment
   A
   B
   C
   D
  16 (7.4)
156 (72.2)
  43 (19.9)
    1 (0.5)
  2 (2.7)
36 (49.3)
31 (42.5)
  4 (5.5)
Induction treatment
   0
   1
   2
   3
   4
  79 (36.6)
  65 (30.1)
  66 (30.5)
    4 (1.9)
    2 (0.9)
31 (42.5)
16 (21.9)
24 (32.8)
  2 (2.7)
  0 (0)
Non-melanoma skin cancer before 
transplant
   No
   Yes
211 (97.7)
    5 (2.3)
68 (93.2)
  5 (6.9)
Warts before transplant
   No
   Yes
189 (87.5)
  27 (12.5)
69 (94.5)
  4 (5.5)
Actinic keratosis before transplant
   No
   Yes
115 (53.2)
101 (46.8)
46 (63.0)
27 (37.0)
Warts after transplant
   No
   Yes
115 (53.2)
101 (46.8)
46 (63.0)
27 (37.0)
Actinic keratosis after transplant
   No
   Yes
170 (78.7)
  46 (21.3)
13 (17.8)
60 (82.2)
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The tumours appeared predominantly in areas exposed 
to the sun (head, neck and distal region of the extremities), 
but 20% of tumours appeared in relatively non-exposed 
areas. Most tumours in these latter areas were BCC.
The cumulative incidence for the development of skin 
cancer showed an ascending curve, going from 20.78% 
5 years after transplant, to 37.35% 10 years after trans-
plant, and 53.08% 15 years after transplant (Fig. 1).
Age at time of transplant
Age at time of transplantation was significantly associa-
ted with an increase in the risk of NMSC on univariate 
and multivariate analysis. 
UV exposure
White skin (phototypes I/II) and light-coloured eyes 
were significantly associated with a higher risk of 
NMSC. High pre-transplant occupational sun exposure 
was associated with a 4-fold increased risk of NMSC vs. 
patients with low exposure on the univariate analysis. 
On the multivariate analysis, only low phototype and 
high pre-transplant occupational sun exposure achieved 
statistical significance. 
Human leukocyte antigen
Patients with a higher number of HLA matches had a 
lower risk of the onset of NMSC on univariate analysis, 
but this trend was not seen on multivariate analysis. 
Immunosuppression 
No statistically significant differences between the 
different treatments were observed. However, immu-
nosuppression regimens with mTOR inhibitors showed 
a clear tendency towards a lower risk of tumours than 
the other treatments.
No statistically significant differences were found in 
the risk of NMSC between patients with and without 
induction treatment. 
Non-melanoma skin cancer prior to transplant
The presence of NMSC prior to transplant was signifi-
cantly associated with an increase in the risk of NMSC 
on the univariate analysis, but this did not achieve 
statistical significance on the multivariate analysis. 
Premalignant lesions and warts
After transplantation, 128 patients developed viral warts, 
5 on the genital area, 40 on the palms and soles, and the 
rest on the trunk and extremities. Most patients develo-
ped fewer than 10 warts, only 5 patients had more than 
10 warts (and all of these 5 patients developed NMSC).
The presence of actinic keratosis prior to, and after 
transplantation, and the detection of warts after trans-
plantation, was associated with a higher risk of NMSC 
in the univariate analysis. However, this did not achieve 
statistical significance in the multivariate analysis. 
Other clinical factors
No statistically significant associations were found bet-
ween the risk of NMSC and gender, alcohol or tobacco 
consumption, family history of cancer, cause of renal 
failure and duration and type of dialysis.
Factors that were definitively associated with a hig-
her risk of NMSC on the multivariate analysis were: 
age at time of transplant, low phototype and high pre-
transplantation occupational sun exposure (Table II).
DISCUSSION
As in the general population, the factors that influence 
the risk of skin cancer after transplant are multiple 
and they interact (1–5). In this study, we examined a 
combination of phenotypic, clinical and environmental 
risk factors for NMSC in kidney transplant recipients 
using the Cox proportional risks model in order to 
identify the independent risk factors associated with 
NMSC. In addition to sun exposure, other clinical and 
environmental factors are associated with the risk of 
NMSC in this population. Accumulated UV radiation 
(especially UVB) is the primary carcinogenic agent 
responsible for NMSC induction, as suggested by the 
fact that the lesions appear almost exclusively in areas 
of skin that are exposed to UV radiation and are more 
numerous in patients who live in sunny countries (4, 
5). Our study demonstrates that white skin and light-
coloured eyes, as well as high level of occupational sun 
exposure, have a higher risk of NMSC after transplant. 
One worrying aspect of our study is the high NMSC 
incidence in transplant patients compared with the rates 
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Fig. 1. Cumulative incidence for skin cancer developing in kidney transplant 
recipients derived from Kaplan–Meier estimation. CI: confidence interval.
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Table II. Univariate analysis and final Cox proportional hazard models for risk of developing skin cancer
Univariate 
relative hazard 95% CI p-value
Final Cox proportional 
relative hazard 95% CI p-value
Age at first transplantation, years 1.09 1.06–1.12 < 0.001 1.06 1.03–1.09 0.001
Dialysis, years 1.01 0.93–1.10 0.742 1.02 0.93–1.10 0.742
Sex
   Male 
   Female
Ref.
0.96 0.60–1.54 0.879 0.98 0.60–1.54 0.879
Phototype
   I–II
   ≥ III
Ref.
0.55 0.32–0.94 0.029 0.50 0.27–0.92 0.026
Eye colour
   Light eyes
   Dark eyes
Ref.
0.57 0.36–0.91 0.021 0.50 0.36–0.91 0.07
Occupational sun exposure
   Low 
   High
Ref.
4.36 2.71–7.01 < 0.001 2.15 1.25–3.71 0.006
Smoking habit
   No
   Ex-smoking
   Yes
Ref.
1.18
1.07
0.58–2.40
0.52–2.14
 0.638
 0.839
 1.10
 1.01
0.58–2.40
0.52–2.14
0.638
0.839
Alcohol consumption
   No
   Ex-alcohol
   Yes
Ref.
1.19
–
 
0.37–3.80
–
 0.764
 0.973
 1.10
 –
0.37–3.80
–
0.764
0.973
Family history of cancer
   No
   Yes
Ref.
1.07 0.67–1.70  0.766 1.07 0.67–1.70 0.766
Dialysis type
   Haemodialysis
   Peritoneal
   Both
Ref.
0.76
1.43
0.32–1.78
0.70–2.89
 0.528
 0.319
0.65
1.40
 0.32–1.78
 0.70–2.89
0.528
0.319
Human leukocyte antigen matches
   ≥ 5
   3–4
   1–2
Ref.
1.55
2.28
0.86–2.79
1.16–4.45
 0.137
 0.016
1.45
2.15
0.86–2.79
1.16–4.45
0.250
0.060
Immunosuppression treatment
   A
   B
   C
   D
Ref.
1.85
1.41
1.76
0.44–7.75
0.34–5.98
0.32–9.72
 0.394
 0.636
 0.516
1.90
1.35
1.70
0.44–7.75
0.34–5.98
0.32–9.72
0.468
0.635
0.512
Induction treatment
   0
   1
   2
   3
   4
Ref.
0.81
0.89
0.59
–
0.44–1.47
0.52–1.52
0.14–2.48
–
 0.489
 0.667
 0.473
 0.970
0.75
0.80
0.45
0.44–1.47
0.52–1.52
0.14–2.48
–
0.320
0.640
0.455
0.890
Non-melanoma skin cancer before transplant
   No
   Yes
Ref.
3.74 1.49–9.39  0.005 2.35 1.49–9.39 0.070
Warts before transplant
   No
   Yes
Ref.
1.20 0.80–1.99  0.468 1.08 0.70–1.80  0.785
Actinic keratosis before transplant
   No
   Yes
Ref.
3.76 1.49–9.46  0.005  3.12 1.49–9.46  0.110
Warts after transplant
   No
   Yes
Ref.
1.40 1.11–1.78  0.006  1.18  1.00–1.50 0.190
Actinic keratosis after transplant
   No
   Yes
Ref.
4.38 2.39–8.03  0.001  4.15 2.39–8.03 0.320
Significant data are shown in bold.
CI: confidence interval.
Acta Derm Venereol 93
426 J. Bernat García et al.
reported in other European studies (2). These differences 
can perhaps be explained because many of the previous 
studies were retrospective and were based on tumour 
registries. The higher sun exposure in our area and the 
combination of retrospective and prospective data in our 
study may explain these differences. This incidence in 
our study is, however, lower than in countries such as 
Australia, where the highest level of NMSC after trans-
plant has been reported, with a cumulative incidence of 
52.2% at 10 years and 82.1% at 20 years (6, 7). 
Age is also an important risk factor. In the study by 
Otley et al. (8), the risk ratio was reported to be 12 ti-
mes greater in patients who received a transplant after 
55 years of age compared with patients who received 
it before 34 years of age. 
In our study the BCC/SCC ratio was 2.21:1, which 
contrasts with other studies where SCC is relatively 
more common. Again, we suggest this difference may 
be due to the fact that majority of previous studies are 
based on tumour registry data (5, 9) where, in many 
cases, only the primary tumour is recorded. In addi-
tion, although histopathology diagnosis is the gold 
standard for the diagnosis of NMSC, lesions treated 
without a histopathology diagnosis are not included in 
these registries and the incidence of BCC is not always 
faithfully estimated. 
The importance of HLA antigen compatibility on the 
survival of the kidney graft is well established. Based 
on studies (10–12), these antigens would also play 
an important role on the development of tumours. In 
the study by Bouwes-Bavinck et al. (10), the risk of 
SCC was increased in recipients with HLA-B antigens 
mismatches. Other studies have suggested a role of 
specific haplotypes in tumour development. These stu-
dies showed a negative association between HLA-A11 
and skin cancer in renal transplant recipients (11), and 
a positive association with HLA-B27 and HLA-DR7 
(12). However, other studies have not confirmed these 
associations (13, 14). In our study, patients with a higher 
number of HLA matches had a lower risk of NMSC 
on the univariate analysis, but this association was not 
confirmed in the multivariate analysis. 
The role of papillomavirus in the aetiopathogenesis of 
NMSC in transplant patients is still controversial. In the 
study by Bouwes-Bavinck et al. (15), actinic keratoses 
and warts were associated with an increased risk of 
NMSC compared with patients without these lesions. 
In our study, warts patients with actinic keratoses after 
transplantation showed an increased risk of NMSC in 
the univariate analysis, but this did not reach statistical 
significance in the multivariate analysis. In this regard 
we must bear in mind the limitations of our study. The 
use of retrospective data poses a greater risk of infor-
mation bias, so we must consider the possibility that 
viral warts could have been considered a “non-serious” 
disorder and not included in the medical record. In a 
study by Arron et al. (16), the HPV genome was more 
frequently detected in early lesions, such as actinic ke-
ratoses and carcinomas in situ, rather than in the more 
advanced SCC, suggesting that the primary role of 
HPV may be in the early stages of skin carcinogenesis. 
Subclinical HPV infection may be significant. Studies 
using polymerase chain reaction (PCR) suggest that 
HPV may be identified in more than 80% of BCCs and 
SCCs in transplant populations, compared with only 
30% in immunocompetent patients (17). However, the 
finding of HPV occurring commonly in normal skin, and 
the lack of particular “high-risk” HPV types, leaves the 
role of HPV in the development of skin cancer open.
With regards to immunosuppressor treatment, group 
A (mTOR inhibitors+mycophenolate) showed a lower 
risk of onset of NMSC than other treatments, though 
these results did not achieve statistical significance, 
probably due to the relatively low number of patients 
in this group. These results are concordant with other 
studies that suggest that mTOR inhibitors could have 
a preventative action in carcinogenesis (18–22). While 
we have been able to identify a clear tendency towards a 
lower incidence of NMSC with mTOR inhibitors, more 
cohort studies with sufficient statistical power will be 
needed in order to validate this tendency. 
While induction treatment does appear to be clearly 
associated with a higher risk of the onset of lympho-
proliferative disorders (23, 24), the role of this treatment 
in the aetiopathogenesis of skin cancer in transplant 
patients is not so clear and there is controversy on the 
subject. In our study, induction treatment did not play 
a role in the onset of NMSC. 
Evaluation of clinical and environmental risk factors 
must be included as part of the clinical routine prior 
to transplantation. Regular examination of the skin, 
instructions on self-monitoring, and the use of protec-
tive measures against the sun, are very important for 
reducing the incidence of skin pathology in transplant 
patients. 
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